Albania
Bosnia-Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Germany
Hungary
Italy
Kosovo
Latvia
Lithuania
Luxembourg
Macedonia
Montenegro
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Spain
Switzerland
Sweden
Turkey
United Kingdom
UAE
Hong Kong
Kuwait
Lebanon
South Africa
English 
Български 
Français 
Deutsch 
Ελληνικά 
Magyar 
Italiano 
Cрпски 
Español
Summary
patients treated
Has anyone ever benefited from stem cell?
For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.
FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.
List of patients
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 101 | Apheresis | Allogeneic | A- Thalassemia | Hematology | 2024 | Standard Therapy | Poland | 11 |
| 102 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 103 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 21 |
| 104 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 22 |
| 105 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 38 |
| 106 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Germany | 41 |
| 107 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 44 |
| 108 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 44 |
| 109 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 110 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 50 |
| 111 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Germany | 50 |
| 112 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 55 |
| 113 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 114 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Germany | 60 |
| 115 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 116 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 44 |
| 117 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 118 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 51 |
| 119 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 34 |
| 120 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 1 |
| 121 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 122 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 20 |
| 123 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 25 |
| 124 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 26 |
| 125 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 28 |
| 126 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 34 |
| 127 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 35 |
| 128 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 37 |
| 129 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 38 |
| 130 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 38 |
| 131 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 40 |
| 132 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 41 |
| 133 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 43 |
| 134 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 51 |
| 135 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 51 |
| 136 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 51 |
| 137 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 138 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 139 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 140 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 141 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 142 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 61 |
| 143 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 61 |
| 144 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 145 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 146 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 147 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 148 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 149 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 150 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 151 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 152 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 153 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 154 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 155 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 156 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 157 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 158 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 159 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 72 |
| 160 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 73 |
| 161 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 77 |
| 162 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 59 |
| 163 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 164 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 58 |
| 165 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 54 |
| 166 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 29 |
| 167 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 168 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 27 |
| 169 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 170 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 171 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 50 |
| 172 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 173 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 30 |
| 174 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 175 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 77 |
| 176 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 60 |
| 177 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 47 |
| 178 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 62 |
| 179 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 180 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 181 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 61 |
| 182 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 183 | Apheresis | Allogeneic | Acute Myelogenous Leukemia- Core-Binding Factor | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 184 | Apheresis | Allogeneic | Acute Myelogenous Leukemia, Post Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 185 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 36 |
| 186 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 46 |
| 187 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 48 |
| 188 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 52 |
| 189 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 190 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 191 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 192 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 71 |
| 193 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 72 |
| 194 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 63 |
| 195 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 32 |
| 196 | Apheresis | Autologous | Acute Myeloid Leukemia – Relapse | Hematology | 2024 | Standard Therapy | Germany | 68 |
| 197 | Apheresis | Allogeneic | Acute Myeloid Leukemia Relapse | Hematology | 2024 | Standard Therapy | Germany | 33 |
| 198 | Apheresis | Allogeneic | Amegakaryocytic/Congenital Thrombocytopenia | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 199 | Apheresis | Allogeneic | Anaplastic Large Cell Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 52 |
| 200 | Apheresis | Allogeneic | Angioimmunoblastic T-Cell Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 47 |